Story perspectives

CRISPR Trial Shows Promise in Lowering Cholesterol Levels

4/6/2026

Summary

Story summary

Christos Soteriou, a 51-year-old man from South Australia, joined a CRISPR trial to lower cholesterol from familial hypercholesterolemia.
After a quadruple bypass, traditional medications failed to control his condition, prompting him to join the trial.
The trial showed promising results with significant reductions in LDL cholesterol and triglycerides, and Soteriou hopes for health benefits.
Experts say the approach could transform heart disease care, though long-term safety remains a concern.

1 of 1

Story summary

Christos Soteriou, a 51-year-old man from South Australia, joined a CRISPR trial to lower cholesterol from familial hypercholesterolemia.
After a quadruple bypass, traditional medications failed to control his condition, prompting him to join the trial.
The trial showed promising results with significant reductions in LDL cholesterol and triglycerides, and Soteriou hopes for health benefits.
Experts say the approach could transform heart disease care, though long-term safety remains a concern.